Company / Working Capital
Mineralys Therapeutics, Inc. Working Capital History
FY2022-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$190.7M
FY2024
5-year range
$104.7M / $238.6M
FY2022-FY2024
Trend
-20.1%
vs FY2023
Sector context
#174 of 213
Health Care
What the data says
Mineralys Therapeutics, Inc.'s working capital of $191M is lower than 82% of companies in the Health Care sector (FY2024). Improved from $105M to $191M over the past 2 years.
Based on SEC 10-K filings.
$191M in FY2024.
Improved from $105M to $191M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 18% in Health CareTop 82% of 213This company $190.7M Sector average $934.6M
▼
-79.6% below sector average
Key checks
Key Insights
- In FY2024, working capital decreased 20.1% year-over-year.
- Ranks #174 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.25 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $190.7M | -20.1% |
| FY2023 | $238.6M | +127.8% |
| FY2022 | $104.7M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026